US20020035133A1 - Medicament containing betasitosterol and/or phytosterol/betasitosterol mixtures - Google Patents

Medicament containing betasitosterol and/or phytosterol/betasitosterol mixtures Download PDF

Info

Publication number
US20020035133A1
US20020035133A1 US09/341,632 US34163299A US2002035133A1 US 20020035133 A1 US20020035133 A1 US 20020035133A1 US 34163299 A US34163299 A US 34163299A US 2002035133 A1 US2002035133 A1 US 2002035133A1
Authority
US
United States
Prior art keywords
betasitosterol
medicament according
acid
phytosterol
mixtures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/341,632
Other versions
US6407085B1 (en
Inventor
Horst Kief
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of US20020035133A1 publication Critical patent/US20020035133A1/en
Application granted granted Critical
Publication of US6407085B1 publication Critical patent/US6407085B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto

Definitions

  • the object of the invention is a medicament which contains betasitosterol - phytoserol mixtures and/or betasitosterol and its physiological metabolites.
  • Processes for dissolving betasitosterol, which in itself is difficult to dissolve, in various oils, paraffins, and glycerins were discovered which open new indications for the use of these substances.
  • esterification of betasitosterol with carboxylic acids opens up therapeutic possibilities for asthma, enflamed intestinal diseases, arterial hypertension, autoimmune diseases of the skin, and for relieving pain which extend far beyond the currently known range for the use of betasitosterol and/or phytosterol/betasitosterol mixtures.
  • Naturally occurring phytosterols are usually a mixture of various sterols (e.g., campesterol, stigmasterol, among others), the most important component of which is the betasitosterol.
  • campesterol e.g., campesterol, stigmasterol, among others
  • betasitosterol e.g., campesterol, stigmasterol, among others
  • it can be derived as an extract from plants, including soy beans or saw palmetto berries by known methods.
  • soy beans or saw palmetto berries by known methods.
  • [0004] 2 As a cholesterol resorption inhibitor.
  • the substance is practically nontoxic and interferes with the release of eicosanoic acid from biomembranes, as a result of which inflammation processes are retarded.
  • a drawback is its insolubility; accordingly it attains a resorption quotient of only around 5% in healthy subjects.
  • a further drawback is that at elevated doses, as it is used for lowering lipids, the resorption quotient and thus the systemic bioavailability drops drastically, i.e., almost no resorption takes place (saturation kinetic).
  • betasitosterol is extremely low in side effects. Even in the case of oral administration of up to 24 g per day, a blood count of only 10 mg is reached due to the low resorption quotient. In the organism, it is 60% to 75% glucoronidated and around 20% is metabolized into cholic acid (C 23 H 36 (OH) 3 COOH) and chenodesoxycholic acid (C 23 H 37 (OH) 2 COOH). Cholic acid is further reduced by intestinal bacteria into desoxycholic acid.
  • betasitosterol and/or its physiologic metabolites in diseases of the skin and the subcutaneous tissue is unknown.
  • no areas of application are known for betasitosterol/phytosterol mixtures in oral administration other than the indications “benign prostatic hyperplasia” and “cholesterol resorption inhibition.”
  • the novelty according to the invention is comprised of esterifying phytosterols, in particular betasitosterol, primarily with carboxylic acids and dicarboxylic acids.
  • betasitosterol (D'ans-Lax, 2-743: soluble in chloroform) which is soluble per se only with difficulty, dissolves in sufficient quantity in linseed oil, safflower oil, and so-called neutral oil if it is allowed to stand longer than 24 h, and very advantageously longer than 36 h at room temperature (neutral oil is a semisynthetic oil of medium-chain triglycerides). In neutral oil and in linseed oil, the solubility of desoxycholic acid corresponds approximately to that of betasitosterols.
  • Desoxycholic acid in the form of its alkali salts and in particular its sodium salt in addition is relatively water soluble; through the addition of sodium desoxycholate, the solubility of betasitosterol in oil is fuirther improved. Upon addition of desoxycholic acid, both oils become opalescent.
  • the solubility of phytosterol/betasitosterol mixtures and betasitosterol metabolites can be accelerated and improved with respect to yield if the effective ingredients are treated in oil, paraffins, stearates, or Vaseline with the application of heat at temperatures of around 70° C. to 160° C., advantageously at 120° C. to 140° C., advantageously over a period of 30 minutes to 3 hours.
  • betasitosterol or sodium desoxycholate is heated in diverse natural and mineral oils, paraffins, commercially-available hypoallergenic stearate mixtures, or Vaseline (2 g substance in 100 ml) to 120° C., both substances dissolve fully within 90 minutes. Upon further heating to 150° C. (at 140° C., betasitosterol becomes liquid), betasitosterol dissolves up to around 15% in stearate mixtures, paraffins, and plant and mineral oils. After cooling, sodium desoxycholate remains clear dissolved in oil, while betasitosterol becomes slightly opalescent in oil. In like manner, betasitosterol and sodium desoxycholate can be introduced into glycerin.
  • both substances dissolve completely clear upon being heated to 120° C.
  • the betasitosterol-glycerin solution is slightly opalescent, while again in this case sodium desoxycholate remains clear.
  • Desoxycholic acid with safflower oil when heated to 120° C. yields a cloudyopalescent emulsion; with glycerin following cooling it yields a white pasty mass which, however, after heating can easily be stirred into any salve base.
  • a special advantage of the betasitosterol-glycerin mixture is its water solubility.
  • the ester of the betasitosterol with carboxylic acids, in particular with.ascorbic acid or lactic acid, also becomes water soluble.
  • the esterification of the betasitosterol with carboxylic acid also has the advantage that the excess amounts of carboxylic acid are relative acidic and thus as a salve component represent a valuable aid for maintaining the protective acidic coating of the skin.
  • the esterification of carboxylic and dicarboxylic acids takes place according to known processes. In like manner, saturated, single and multiple unsaturated oleic acid esters, stearolic acid esters, and triglycerides can be formed according to the state of the art with acid catalysts using remaining unesterified portions.
  • phytosterol/betasitosterol mixtures when they are dissolved in the above described form in oil, are stirred into a salve base alone or in a mixture with sodium desoxycholate in aqueous solution in a concentration of 0.5 to 2.0% and the salve base is applied to the skin, the itching of neurodermatitis usually is eased after only 2 to 5 minutes. Inflammation processes with redness and swelling are alleviated after 24 to 48 hours. Thus a histamine antagonistic as well as a cortisone-like effect is determined, but without the side effects of the hormone.
  • betasitosterol or desoxycholic acid in the form of alkali desoxycholates, in particular of sodium desoxycholate or both substances together are applied in a resorbable salve or gel base to inflamed swellings or for arthrosis, arthritis, or soft-tissue rheumatism, a lasting reduction of pain and reduction of swelling of the inflamed area is achieved within 2 to 3 days.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

The invention relates to a medicament containing mixtures of betasitosterol and phytosterol and/or betasitosterol and its physiological metabolites. Processes were discovered for dissolving betasitosterol, which in itself is difficult to dissolve, in various oils and paraffins and in glycerin, which processes offer new indications for the use of these substances. In addition, the esterification of the betasitosterol with carboxylic acids opens up therapeutic possibilities in asthma, inflammatory intestinal diseases, arterial hypertension, autoimmune diseases of the skin and pain relief which far exceed the currently known range of uses of betasitosterol and phytosterol/betasitosterol mixtures.

Description

  • The object of the invention is a medicament which contains betasitosterol - phytoserol mixtures and/or betasitosterol and its physiological metabolites. Processes for dissolving betasitosterol, which in itself is difficult to dissolve, in various oils, paraffins, and glycerins were discovered which open new indications for the use of these substances. In addition, the esterification of betasitosterol with carboxylic acids opens up therapeutic possibilities for asthma, enflamed intestinal diseases, arterial hypertension, autoimmune diseases of the skin, and for relieving pain which extend far beyond the currently known range for the use of betasitosterol and/or phytosterol/betasitosterol mixtures. [0001]
  • Naturally occurring phytosterols are usually a mixture of various sterols (e.g., campesterol, stigmasterol, among others), the most important component of which is the betasitosterol. For example, it can be derived as an extract from plants, including soy beans or saw palmetto berries by known methods. For decades it has been used in medicine with two indications: [0002]
  • [0003] 1. As a medication for benign prostatic hyperplasia.
  • [0004] 2. As a cholesterol resorption inhibitor.
  • The substance is practically nontoxic and interferes with the release of eicosanoic acid from biomembranes, as a result of which inflammation processes are retarded. A drawback is its insolubility; accordingly it attains a resorption quotient of only around 5% in healthy subjects. A further drawback is that at elevated doses, as it is used for lowering lipids, the resorption quotient and thus the systemic bioavailability drops drastically, i.e., almost no resorption takes place (saturation kinetic). [0005]
  • The use of betasitosterol is extremely low in side effects. Even in the case of oral administration of up to 24 g per day, a blood count of only 10 mg is reached due to the low resorption quotient. In the organism, it is 60% to 75% glucoronidated and around 20% is metabolized into cholic acid (C[0006] 23H36(OH)3COOH) and chenodesoxycholic acid (C23H37(OH)2COOH). Cholic acid is further reduced by intestinal bacteria into desoxycholic acid.
  • The percutaneous use of betasitosterol and/or its physiologic metabolites in diseases of the skin and the subcutaneous tissue is unknown. In like manner, no areas of application are known for betasitosterol/phytosterol mixtures in oral administration other than the indications “benign prostatic hyperplasia” and “cholesterol resorption inhibition.” [0007]
  • It is known that the resorption quotient, distributability, and excretion quotient, in short the pharmacokinetics of a preparation, are very strongly dependent not only on its chemical partners, but also on its physical solubility in various media. [0008]
  • The novelty according to the invention is comprised of esterifying phytosterols, in particular betasitosterol, primarily with carboxylic acids and dicarboxylic acids. [0009]
  • In addition, dissolving processes according to the invention for phytosterol/betasitosterol mixtures were found which make possible additional therapeutic uses, for example against diseases of the skin such as psoriasis and neurodermatitis. Lactic acid, ascorbic acid, gluconic acid, and tartaric acid are particularly advantageous for the esterifying due to their physiological effectiveness in the organism, their therapeutic reliability, and their lack of side effects. [0010]
  • The advantage of these compounds is to be found in the fact that with proper selection of the carboxylic acid, both reaction substances in themselves are nontoxic. In like manner, for example, the betasitosterol, ascorbic, and gluconic acid esters which are thereby generated are free of side effects and very well tolerated when taken orally. [0011]
  • For percutaneous use, the binding of phytosterol/betasitosterol mixtures to alcohols , but also to diols and triols, in the latter case the formation of a triglyceride is particularly suitable. Straight-chained primary alcohols, which have proven to be of value in skin care and therapy, are particularly suitable for this. betasitosterol (D'ans-Lax, 2-743: soluble in chloroform) which is soluble per se only with difficulty, dissolves in sufficient quantity in linseed oil, safflower oil, and so-called neutral oil if it is allowed to stand longer than 24 h, and very advantageously longer than 36 h at room temperature (neutral oil is a semisynthetic oil of medium-chain triglycerides). In neutral oil and in linseed oil, the solubility of desoxycholic acid corresponds approximately to that of betasitosterols. Desoxycholic acid in the form of its alkali salts and in particular its sodium salt in addition is relatively water soluble; through the addition of sodium desoxycholate, the solubility of betasitosterol in oil is fuirther improved. Upon addition of desoxycholic acid, both oils become opalescent. [0012]
  • The solubility of phytosterol/betasitosterol mixtures and betasitosterol metabolites can be accelerated and improved with respect to yield if the effective ingredients are treated in oil, paraffins, stearates, or Vaseline with the application of heat at temperatures of around 70° C. to 160° C., advantageously at 120° C. to 140° C., advantageously over a period of 30 minutes to 3 hours. [0013]
  • If betasitosterol or sodium desoxycholate is heated in diverse natural and mineral oils, paraffins, commercially-available hypoallergenic stearate mixtures, or Vaseline (2 g substance in 100 ml) to 120° C., both substances dissolve fully within 90 minutes. Upon further heating to 150° C. (at 140° C., betasitosterol becomes liquid), betasitosterol dissolves up to around 15% in stearate mixtures, paraffins, and plant and mineral oils. After cooling, sodium desoxycholate remains clear dissolved in oil, while betasitosterol becomes slightly opalescent in oil. In like manner, betasitosterol and sodium desoxycholate can be introduced into glycerin. In this case, both substances dissolve completely clear upon being heated to 120° C. Upon cooling, the betasitosterol-glycerin solution is slightly opalescent, while again in this case sodium desoxycholate remains clear. Desoxycholic acid with safflower oil when heated to 120° C. yields a cloudyopalescent emulsion; with glycerin following cooling it yields a white pasty mass which, however, after heating can easily be stirred into any salve base. [0014]
  • Microscopic monitoring of the opalescent phases shows that upon cooling, the solubility of the betasitosterol/phytosterol mixture drops, the dispersed phases partially separate, so that in part a suspension develops. [0015]
  • The solubility of phytosterol/betasitosterol mixtures and betasitosterol metabolites in oil, stearates, and glycerin under the described conditions without the assistance of emulsifying agents is of great therapeutic advantage, since the atopic skin easily becomes allergic and the potential danger of inducing an inflammation process is increased through a multiplicity of substances in a salve. [0016]
  • A special advantage of the betasitosterol-glycerin mixture is its water solubility. The ester of the betasitosterol with carboxylic acids, in particular with.ascorbic acid or lactic acid, also becomes water soluble. The esterification of the betasitosterol with carboxylic acid also has the advantage that the excess amounts of carboxylic acid are relative acidic and thus as a salve component represent a valuable aid for maintaining the protective acidic coating of the skin. The esterification of carboxylic and dicarboxylic acids takes place according to known processes. In like manner, saturated, single and multiple unsaturated oleic acid esters, stearolic acid esters, and triglycerides can be formed according to the state of the art with acid catalysts using remaining unesterified portions. [0017]
  • Through the formation of betasitosterol-oleic acid or stearic acid esters on the one hand and glycerin-ascorbic acid and lactic acid esters on the other, it is possible to apply cortisone-like structures to the skin both in fat-soluble form as well as in water-soluble preparations and thus to ensure a very good diffusion through the upper layers of the skin. [0018]
  • If phytosterol/betasitosterol mixtures, when they are dissolved in the above described form in oil, are stirred into a salve base alone or in a mixture with sodium desoxycholate in aqueous solution in a concentration of 0.5 to 2.0% and the salve base is applied to the skin, the itching of neurodermatitis usually is eased after only 2 to 5 minutes. Inflammation processes with redness and swelling are alleviated after 24 to 48 hours. Thus a histamine antagonistic as well as a cortisone-like effect is determined, but without the side effects of the hormone. In the case of psoriasis, the formation of scales is often reduced even in extreme cases only 24 hours after the first application, particularly with the use of the metabolite desoxycholic acid. Here again the use of such substances is completely unproblematic in contrast to a salve with a component of vitamin-D-like structure, which as a result of the resorption of the vitamin-D-like molecule can be applied only to a limited extent because of the danger of overdosing and thus the influencing of calcium metabolism. [0019]
  • If betasitosterol or desoxycholic acid in the form of alkali desoxycholates, in particular of sodium desoxycholate or both substances together are applied in a resorbable salve or gel base to inflamed swellings or for arthrosis, arthritis, or soft-tissue rheumatism, a lasting reduction of pain and reduction of swelling of the inflamed area is achieved within [0020] 2 to 3 days.
    •
  • While only prostatic hyperplasia and high cholesterol are known as indications for betasitosterol in oral administration, and despite knowledge of the prostaglandin inhibition, it has not been possible to find an additional indication in this regard, the combinations according to the invention of phytosterol/betasitosterol with (di-)carboxylic acids, in particular ascorbic acid administered orally have clear, significant effects which go well beyond the old indications. [0021]
  • 1. One of the first steps in the triggering of pain is the emission of mediators of the prostaglandin cascade through the inflammation process. The substance acts in this regard promptly and limits pain both for patients with rheumatism as well as in those with malignant diseases. [0022]
  • 2. Arterial hypertension is often triggered through inflammation processes at the kidneys. The substance acts as an antihypertensive agent upon this indication rapidly and without side effects or it intensifies the effect of specific antihypertensive agents. [0023]
  • 3. Some atopic and autoimmune-induced skin diseases also take a pathophysiological “side road” through prostaglandin cascade. Here, too, clear improvements of the condition of the skin are achieved without side effects occurring. [0024]
  • 4. Spasm of the smooth bronchial muscles in asthma bronchial is in most cases reduced within a few minutes. The substance group thus results in considerable reductions in applications of cortisone with its side effects. [0025]
  • 5. Pain and inflammation processes in ulcerated colitis and Crohn's disease arc reduced. [0026]
  • These indications are particularly applicable for esters of betasitosterol with ascorbic acid and lactic acid. The new substance group thus demonstrates a spectrum of effectiveness which extends far beyond that which these substances can claim individually. [0027]

Claims (10)

1. Medicament for use for inflamed processes of the diseased organism or its organs, in particular of the skin and the subcutaneous tissue, which contains as effective ingredient
a) betasitosterol and cholic acid, chenodeoxycholic acid, desoxycholic acid, or water-soluble alkali salts as a suspension or in physically dissolved form, or
b) betasitosterol ascorbic acid ester, betasitosterol tartaric acid ester, or betasitosterol gluconic acid ester.
2. Medicament according to claim 1 characterized in that it contains water-soluble alkali salts of cholic acid, chenodeoxycholic acid, or desoxycholic acid.
3. Medicament according to claim 2 characterized in that it contains sodium desoxycholate.
4. Medicament according to claim 1 characterized in that it contains betasitosterol ascorbic acid ester.
5. Medicament according to claim 1 characterized in that it contains betasitosterol gluconic acid ester.
6. Medicament according to one of claims 1 through 5 characterized in that it is indicated for inflamed diseases of the skin and of the subcutaneous tissue, in particular neurodermatitis and psoriasis.
7. Medicament according to claim 4 characterized in that it is indicated for relief of pain, in particular for rheumatism and malignant diseases.
8. Medicament according to claim 4 characterized in that it is indicated for arterial hypertension.
9. Medicament according to claim 4 characterized in that it is indicated for asthma.
10. Medicament according to claim 4 characterized in that it is indicated for ulcerated colitis and Crohn's disease.
US09/341,632 1997-01-16 1998-01-16 Medicament containing betasitosterol and/or phytosterol/betasitosterol mixtures Expired - Fee Related US6407085B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19701264 1997-01-16
DE19701264A DE19701264A1 (en) 1997-01-16 1997-01-16 Remedies containing betasitosterol and / or phytosterol / betasitosteric mixtures
DE19701264.7 1997-01-16
PCT/EP1998/000227 WO1998031372A1 (en) 1997-01-16 1998-01-16 Medicament containing betasitosterol and/or phytosterol/betasitosterol mixtures

Publications (2)

Publication Number Publication Date
US20020035133A1 true US20020035133A1 (en) 2002-03-21
US6407085B1 US6407085B1 (en) 2002-06-18

Family

ID=7817498

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/341,632 Expired - Fee Related US6407085B1 (en) 1997-01-16 1998-01-16 Medicament containing betasitosterol and/or phytosterol/betasitosterol mixtures

Country Status (5)

Country Link
US (1) US6407085B1 (en)
EP (1) EP0967981A1 (en)
AU (1) AU6094598A (en)
DE (1) DE19701264A1 (en)
WO (1) WO1998031372A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI974648A (en) 1997-09-09 1999-05-06 Raisio Benecol Oy Hydroxy acid, lactic acid and hydroxyalkanoate esters and their uses
FI115527B (en) * 1998-10-16 2005-05-31 Upm Kymmene Oyj Use of plant sterol derivatives and products containing them
KR100711861B1 (en) * 1999-06-23 2007-04-25 포비스 메디-테크 인코포레이티드 Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
US20080182801A1 (en) * 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
GB0513888D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
US7615546B2 (en) * 2005-08-19 2009-11-10 Bioderm Research Topical delivery system for phytosterols
KR102527103B1 (en) 2016-06-06 2023-04-28 크리스탈 파마 에스.에이.유. Process for producing deoxycholic acid and intermediates useful in the production of deoxycholic acid

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3004043A (en) * 1959-10-09 1961-10-10 Eastman Kodak Co Water-soluble vegetable oil sterol derivatives
US4254111A (en) * 1978-07-05 1981-03-03 Roecar Holdings (Netherlands Antilles) Nv Sterolin products
US4260603A (en) 1979-01-02 1981-04-07 Pegel Karl H Sterol glycoside with activity as prostaglandin synthetase inhibitor
JPS57131716A (en) * 1981-01-28 1982-08-14 Hiroshi Sekimoto Cosmetic for exclusive use to plantar skin
AU2272883A (en) * 1982-12-22 1984-06-28 Herpes Pharmaceutical Inc. Pharmaceutical compositions of steriods for treatment of herpes simplex infections
SU1138162A1 (en) * 1983-04-28 1985-02-07 Ленинградская Ордена Ленина Лесотехническая Академия Им.С.М.Кирова Creme for lips
DE3416112A1 (en) * 1984-04-30 1985-10-31 Roecar Holdings (Netherlands Antilles) N.V., Willemstad, Curacao, Niederländische Antillen USE OF STEROLINES AND SPIROKETALINES AS LIPOXYGENAS REGULATORS
US4897224A (en) * 1985-03-05 1990-01-30 Morinaga Milk Industry Co., Ltd. Method for producing ferulyl stanol derivatives
DE3546360A1 (en) * 1985-12-30 1987-07-23 Mueller Karl Heinz Dr Use of deoxycholic acid for disturbances of wound healing
JPS63156727A (en) * 1986-12-19 1988-06-29 Q P Corp Remedy for dermatosis and adhesive plaster using said remedy
JPH0225425A (en) * 1988-07-13 1990-01-26 Nippon Ham Kk Antihypertensive agent
DE3829641A1 (en) * 1988-09-01 1990-03-15 Roecar Holdings Nv TRANSDERMAL APPLICABLE PHARMACEUTICAL PREPARATIONS WITH STEROLINES AND / OR SPIROKETALINES
JP2819140B2 (en) * 1989-01-18 1998-10-30 ポーラ化成工業株式会社 Cosmetics
US5574063A (en) * 1989-10-12 1996-11-12 Perricone; Nicholas V. Method and compositions for topical application of ascorbic acid fatty acid esters for treatment and/or prevention of skin damage
GB2238476A (en) * 1989-11-04 1991-06-05 K T Lalvani Therapeutic aquatic animal and garlic products
DE69213804T2 (en) * 1991-03-28 1997-03-27 Rooperol Na Nv Compositions of phytosterols with phytosterolins as immunomodulators
TW212761B (en) * 1991-04-09 1993-09-11 Takeda Pharm Industry Co Ltd
CH680704A5 (en) * 1991-05-15 1992-10-30 Medichemie Ag
RU2069557C1 (en) * 1992-01-31 1996-11-27 ТОО "Фитолон" Cream for skin
JP2983125B2 (en) * 1993-06-02 1999-11-29 株式会社ノエビア External preparation for skin
DE4328799A1 (en) * 1993-08-27 1995-03-02 Hoechst Ag Process for obtaining pharmacologically active compounds from complex mixtures
JP3126583B2 (en) * 1994-01-13 2001-01-22 ロンシャン シュ Burn treatment agent, method for producing the same, and treatment method using the same
JPH07277986A (en) * 1994-04-08 1995-10-24 Kazuo Hosoya Antibacterial agent ingredient containing bile acid salt as main ingredient and used against methicillin-resistant staphylococcus aureus
JP3493459B2 (en) * 1994-05-17 2004-02-03 株式会社大塚製薬工場 External preparation for skin
US5709868A (en) * 1995-09-20 1998-01-20 Perricone; Nicholas V. Lipoic acid in topical compositions
JP2978432B2 (en) * 1995-12-21 1999-11-15 日誠マリン工業株式会社 Pharmaceutical composition for reducing antinuclear antibody and pharmaceutical composition for reducing rheumatoid factor
US5965618A (en) * 1997-11-17 1999-10-12 Perricone; Nicholas V. Treatment of scar tissue using lipoic acid

Also Published As

Publication number Publication date
AU6094598A (en) 1998-08-07
WO1998031372A1 (en) 1998-07-23
US6407085B1 (en) 2002-06-18
EP0967981A1 (en) 2000-01-05
DE19701264A1 (en) 1998-07-23

Similar Documents

Publication Publication Date Title
DE60112102T2 (en) COMBINATION OF A NO-DONOR AND ANTIOXIDANE FOR THE TREATMENT OF SEXUAL DISORDERS
JP2768465B2 (en) Complexes of saponins and phospholipids and pharmaceutical and cosmetic compositions containing them
US20100098786A1 (en) Formulation containing a carboxylic acid or an ester thereof
EP2301525A1 (en) Topical ibuprofen formulation
US6407085B1 (en) Medicament containing betasitosterol and/or phytosterol/betasitosterol mixtures
PT719145E (en) NITRIC OXIDE DERIVATIVE COMPOSITION FOR TREATMENT OF ANAL DISORDERS
TW200918550A (en) Synthetic bile acid composition, method, and preparation
JPS60100517A (en) Radiation remedy for ulcer and method
JPH08500092A (en) Dermatological composition
JPH05178744A (en) Method for medical treatment using fatty acid
WO1983000294A1 (en) Micellular drug delivery system
JPH02174719A (en) Percutaneously administrative drug composition containing steroin and/or spiroketaline
JP3508042B2 (en) Ceramide synthesis promoter
EP1501480B1 (en) Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs
JPH0399013A (en) Therapy with fatty acid
CN105125592A (en) Medicine containing toad venom lipid-soluble substances and preparation method thereof
CH637829A5 (en) MEDICINAL PRODUCTS WITH EFFECT AS PROSTAGLANDIN SYNTHETASE INHIBITOR.
JP2002535479A (en) Method for obtaining an oil rich in hydroxyoctadecadienic fatty acid (HODE) or an ester thereof from a mixture containing linoleic acid or an ester thereof
LEE Prostaglandins and the renal antihypertensive and natriuretic endocrine function
JPH01301623A (en) Use of ethisteron for local treatment of pimple or androgenic loss of hair
EP0366156B1 (en) Composition for the treatment of diseases of the veins and the anal region
EP0521057A1 (en) Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use.
JP3689137B2 (en) Topical agent for treatment of allergic skin disease
EP0965340A1 (en) Dermatologic preparation
JP3072768B2 (en) Pigmentation treatment

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAT HOLDER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: LTOS); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

REFU Refund

Free format text: REFUND - PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: R1551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362